Plasminogen activator inhibitor-1 contributes to the deleterious effect of obesity on the outcome of thrombotic ischemic stroke in mice

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 8, 2007, Pages 1726-1731

  Nagai, N ^a   Van Hoef, B ^a   Lijnen, H Roger ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Obesity; Plasminogen activator inhibitor 1; Stroke

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DNA MODIFICATION; LEAN BODY WEIGHT; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; WILD TYPE;

ANIMALS; CEREBROVASCULAR ACCIDENT; FEMALE; INFARCTION, MIDDLE CEREBRAL ARTERY; ISCHEMIA; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOSIS; TIME FACTORS; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 34447640693     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02631.x     Document Type: Article

References (46)

1. Hankey GJ. Potential new risk factors for ischemic stroke. What is their potential?. Stroke 2006; 37: 2181-8.
2. Rashid MN, Fuentes F, Touchon RC, Wehner PS. Obesity and the risk for cardio-vascular disease. Prev Cardiol 2003; 6: 42-7.
3. Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, Hill M, Howard G, Howard VJ, Jacobs B, Levine SR, Mosca L, Sacco RL, Sherman DG, Wolf PA, del Zoppo GJ. Primary prevention of ischemic stroke; a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 2001; 32: 280-99.
4. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67: 968-77.
5. Kurth T, Gaziano JM, Berger K, Kase CS, Rexrode KM, Cook NR, Buring JE, Manson JE. Body mass index and the risk of stroke in men. Arch Intern Med 2002; 162: 2557-62.
6. Pyorala M, Miettinen H, Laakso M, Pyorala K. Hyperinsulinemia and the risk of stroke in healthy middle-aged men: The 22-year follow-up results of the Helsinki Policemen Study. Stroke 1998; 29: 1860-6.
7. Shinton R, Shipley M, Rose G. Overweight and stroke in the Whitehall Study. J Epidemiol Commun Health 1991; 45: 138-42.
8. Abbott RD, Behrens GR, Sharp DS, Rodriguez BL, Burchfiel CM, Ross GW, Yano K, Curb JD. Body mass index and thromboembolic stroke in nonsmoking men in older middle age. The Honolulu Heart Program. Stroke 1994; 25: 2370-6.
9. Rexrode KM, Hennekens CH, Willett WC, Colditz GA, Stampfer MJ, Rich-Edwards JW, Speizer FE, Manson JE. A prospective study of body mass index, weight change, and risk of stroke in women. JAMA 1997; 277: 1539-45.
10. Lindenstrom E, Boysen G, Nyboe J. Risk factors for stroke in Copenhagen, Denmark. II. Life-style factors. Neuroepidemiology 1993; 12: 43-50.
11. Selmer R, Tverdal A. Body mass index and cardiovascular mortality at different levels of blood pressure: A prospective study of Norwegian men and women. J Epidemiol Commun Health 1995; 49: 265-70.
12. Dey DK, Rothenberg E, Sudnh V, Bosaeus I, Steen B. Waist circumference, body mass index, and risk for stroke in older people: A 15 year longitudinal population study of 70-year-olds. J Am Geriatr Soc 2002; 50: 1510-8.
13. Song YM, Sung J, Smith GD, Ebrahim S. Body mass index and ischemic and hemorrhagic stroke. A prospective study in Korean men. Stroke 2004; 35: 831-6.
14. Haheim LL, Holme I, Hjermann I, Leren P. Risk factors of stroke incidence and mortality. A 12-year follow-up of the Oslo study. Stroke 1993; 24: 1484-9.
15. Shaper AG, Wannamethee SG, Walker M. Body weight: Implications for the prevention of coronary heart disease, stroke, and diabetes mellitus in a cohort study of middle aged men. Br Med J 1997; 314: 1311-7.
16. Hart CL, Hole DJ, Smith GD. Risk factors and 20-year stroke mortality in men and women in the Renfrew/Paisley study in Scotland. Stroke 1999; 30: 1999-2007.
17. Harmsen P, Rosengren A, Tsipogianni A, Wilhelmsen L. Risk factors for stroke in middle-aged men in Goteborg, Sweden. Stroke 1990; 21: 223-9.
18. Walker SP, Rimm EB, Ascherio A, Kawachi I, Stampfer MJ, Willett WC. Body size and fat distribution as predictors of stroke among US men. Am J Epidemiol 1996; 144: 1143-50.
19. Suk SH, Sacco RL, Boden-Albala B, Cheun JF, Pittman JG, Elkind MS, Paik MC. Abdominal obesity and risk of ischemic stroke: The Northern Manhattan Stroke Study. Stroke 2003; 34: 1586-92.
20. Jood K, Jern C, Wilhelmsen L, Rosengren A. Body mass index in mid-life is associated with a first stroke in men: A prospective population study over 28 years. Stroke 2004; 35: 2764-9.
21. Kurth T, Gaziano JM, Rexrode KM, Kase CS, Cook NR, Manson JE, Buring JE. Prospective study of body mass index and risk of stroke in apparently healthy women. Circulation 2005; 111: 1992-8.
22. Juhan-Vague I, Morange PE, Alessi MC. The insulin resistance syndrome: implications for thrombosis and cardiovascular disease. Pathophysiol Haemost Thromb 2002; 32: 269-73.
23. Mutch NJ, Wilson HM, Booth NA. Plasminogen activator inhibitor-1 and haemostasis in obesity. Proc Nutr Soc 2001; 60: 341-7.
24. Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 2005; 3: 35-45.
25. Carmeliet P, Kieckens L, Schoonjans L, Ream B, Van Nuffelen A, Prendergast G, Cole M, Bronson R, Collen D, Mulligan RC. Plasminogen activator inhibitor-1 gene-deficient mice. Generation by homologous recombination and characterization. J Clin Invest 1993; 92: 2746-55.
26. Giles AR. Guidelines for the use of animals in biomedical research. Thromb Haemost 1987; 58: 1078-84.
27. Nagai N, Demarsin E, Van Hoef B, Wouters S, Cingolani D, Laroche Y, Collen D. Recombinant human microplasmin: Production and potential therapeutic properties. J Thromb Haemost 2003; 1: 307-13.
28. Voros G, Maquoi E, Demeulemeester D, Clerx N, Collen D, Lijnen HR. Modulation of angiogenesis during adipose tissue development in murine models of obesity. Endocrinology 2005; 146: 4545-54.
29. Zhao BQ, Ikeda Y, Ihara H, Urano T, Fan W, Mikawa S, Suzuki Y, Kondo K, Sato K, Nagai N, Umemura K. Essential role of endogenous tissue plasminogen activator through matrix metalloproteinase 9 induction and expression on heparin-produced cerebral hemorrhage after cerebral ischemia in mice. Blood 2004; 103: 2610-6.
30. Suzuki Y, Nagai N, Collen D. Comparative effects of microplasmin and tissue-type plasminogen activator (tPA) on cerebral hemorrhage in a middle cerebral artery occlusion model in mice. J Thromb Haemost 2004; 2: 1617-21.
31. Suzuki Y, Chen F, Ni Y, Marchal G, Collen D, Nagai N. Microplasmin reduces ischemic brain damage and improves neurological function in a rat stroke model monitored with MRI. Stroke 2004; 10: 2402-6.
32. Declerck PJ, Verstreken M, Collen D. Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice. Thromb Haemost 1995; 74: 1035-9.
33. Kurl S, Laukkanen JA, Niskanen L, Laaksonen D, Sivenius J, Nyyssonen K, Salonen JT. Metabolic syndrome and the risk of stroke in middle-aged men. Stroke 2006; 37: 806-11.
34. Chen HJ, Bai CH, Yeh WT, Chiu HC, Pan WH. Influence of metabolic syndrome and general obesity on the risk of ischemic stroke. Stroke 2006; 37: 1060-4.
35. Kawamoto R, Tomita H, Oka Y, Kodama A. Metabolic syndrome as a predictor of ischemic stroke in elderly persons. Int Med 2005; 44: 922-7.
36. Samad F, Yamamoto K, Loskutoff DJ. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. J Clin Invest 1996; 97: 37-46.
37. Lijnen HR, Maquoi E, Demeulemeester D, Van Hoef B, Collen D. Modulation of fibrinolytic and gelatinolytic activity during adipose tissue development in a mouse model of nutritionally induced obesity. Thromb Haemost 2002; 88: 345-53.
38. Ribo M, Molina CA, Delgado P, Rubiera M, Delgado-Mederos R, Rovira A, Munuera J, Alvarez-Sabin J. Hyperglycemia during ischemia rapidly accelerates brain damage in stroke patients treated with t-PA. J Cereb Blood Flow Metab 2007; DOI: 10.1038/sj.jcbfm.9600460.
39. Ribo M, Montaner J, Molina CA, Arenillas JF, Santamarina E, Alvarez-Sabin J. Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator. Thromb Haemost 2004; 91: 1146-51.
40. Nagai N, Suzuki Y, Van Hoef B, Lijnen HR, Collen D. Effects of plasminogen activator inhibitor-1 on ischemic brain injury in permanent and thrombotic middle cerebral artery occlusion models in mice. J Thromb Haemost 2005; 3: 1379-84.
41. Fisher M, Francis R. Altered coagulation in cerebral ischemia. Platelet, thrombin, and plasmin activity. Arch Neurol 1990; 47: 1075-9.
42. Zhang ZG, Chopp M, Goussev A, Lu D, Morris D, Tsang W, Powers C, Ho KL. Cerebral microsvascular obstruction by fibrin is associated with upregulation of PAI-1 acutely after onset of focal embolic ischemia in rats. J Neurosci 1999; 19: 10898-907.
43. Hosomi N, Lucero J, Heo JH, Koziol JA, Copeland BR, del Zoppo GJ. Rapid differential endogenous plasminogen activator expression after acute middle cerebral artery occlusion. Stroke 2001; 32: 1341-8.
44. Nagai N, De Mol M, Lijnen HR, Carmeliet P, Collen D. Role of plasminogen system components in focal cerebral ischemic infarction: A gene targeting and gene transfer study in mice. Circulation 1999; 99: 2440-4.
45. Tsirka SE, Gualandris A, Amaral DG, Strickland S. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 1995; 377: 340-4.
46. Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence DA. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 2003; 112: 1533-40.